Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., . . . Powles, T. (2019). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): Overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol.
Citação norma ChicagoPetrylak, Daniel P., et al. "Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-blind, Phase 3 Trial." Lancet Oncol 2019.
MLA citiranjePetrylak, Daniel P., et al. "Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Platinum-based Therapy (RANGE): Overall Survival and Updated Results of a Randomised, Double-blind, Phase 3 Trial." Lancet Oncol 2019.